First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.

20 Although some uncommon EGFR mutations were reported to derive clinical benefit from immunotherapy, 21 , 22 the correlation between NSCLC with EGFR ex20ins and its response to ICI was controversial by several studies, covering a possible trend that ICI might not be a favorable option for ex20ins patients. 8 , 10 , 12 , 22 , 23 , 24 , 25 , 26 Yet, there lacks comprehensive study evaluating the exact efficacy of combination therapy with chemotherapy plus Ai or ICI for advanced NSCLC with EGFR ex20ins in China.

also in 1,410 other papers